Analysts await Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) to report earnings on Mar, 15 for the fiscal quarter ending Dec 2015.

The biggest institutional shareholders in Aralez Pharmaceuticals Inc. include Par Capital Management Inc which owns 4 million shares in the company valued at $25.31 million. Deerfield Management Co is the second biggest holder with 2 million shares currently valued at 10.77 million whilst BlackRock Fund Advisors has 1 million shares valued at 8.02 million.

Total shares held by institutions as of the most recent company filings are 20,015 with a reported 2,533 bought and 0 sold. These holdings make up 0.06% of the company’s outstanding shares.

Currently insiders hold 7,244,544 shares in the business which makes up 22.10% of shares. The biggest holder currently is Mr. Adrian Adams who owns 2,944,888 shares (8.98% of those outstanding), whilst Mr. Andrew I. Koven holds 1,476,674 (4.51% of shares outstanding) and Mr. Robert Harris holds 736,594 (2.25% of shares outstanding).

The stock decreased 2.52% or $0.15 during the last trading session, hitting $6.50. Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) has fallen 52.31% over the past 6 months and is downtrending.